U.S. Markets close in 1 hr 18 mins
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • Dow 30

    35,870.95
    -60.10 (-0.17%)
     
  • Nasdaq

    15,993.71
    +72.14 (+0.45%)
     
  • Russell 2000

    2,363.59
    -13.42 (-0.56%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    57,599.12
    -570.07 (-0.98%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

Galapagos' Another Psoriasis Candidate Shows Efficacy, Safety Profile In Mid-Stage Study

·1 min read
  • Galapagos NV (NASDAQ: GLPG) reported topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients.

  • At Week 4, four out of 10 patients in the high dose group had at least a 50% improvement in severity index (PASI 50) from baseline, compared to one out of 10 subjects on placebo.

  • No subjects achieved a PASI 50 response on the low dose of GLPG3667.

  • The four responders in the high dose group of GLPG3667 achieved a 52%, 65%, 74%, and 81% improvement respectively in their PASI scores from baseline, while the subject on placebo improved by 52%.

  • Positive efficacy signals were also observed with the high dose for other endpoints versus placebo at Week 4.

  • GLPG3667 was well tolerated. One patient in the low dose group interrupted the study for one day for exacerbation of psoriasis.

  • The majority of treatment-related adverse events were mild in nature and transient. No deaths or serious adverse events were reported.

  • The Company plans to initiate a global GLPG3667 Phase 2b program in psoriasis in 2022.

  • Related link: Galapagos SIK inhibitor failed to show positive outcomes in ulcerative colitis, rheumatoid arthritis patients

  • Price Action: GLPG shares are down 10.9% at $58.62 during the premarket session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.